Interferon-β alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke

Tissue plasminogen activator (tPA) is the only US Food and Drug Administration (FDA)–approved drug for ischemic stroke. However, delayed tPA administration is associated with increased risk of blood-brain barrier (BBB) disruption and hemorrhagic transformation (HT). Interferon-β (IFNβ), an FDA-appro...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2020-09, Vol.4 (18), p.4366-4381
Hauptverfasser:	Kuo, Ping-Chang, Weng, Wen-Tsan, Scofield, Barbara A., Furnas, Destin, Paraiso, Hallel C., Intriago, Alexander J., Bosi, Kristopher D., Yu, I-Chen, Yen, Jui-Hung
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Brain Ischemia - drug therapy Endothelial Cells Interferon-beta Ischemic Stroke Matrix Metalloproteinase 3 Stroke - drug therapy Thrombosis and Hemostasis Tissue Plasminogen Activator United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!